Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applied Digital Corporation (APLD) vs Incyte Corporation (INCY) Price & Performance

Applied Digital CorporationTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Applied Digital Corporation vs Incyte Corporation — how do they compare? Applied Digital Corporation trades at $30.62 (market cap $8.55B), while Incyte Corporation trades at $121.47 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 2.9× Applied Digital Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.

APLDINCY
Market Cap
$8.55B$24.54B
Sector
TechnologyHealth
52-Week High
$49.65$129.93
52-Week Low
$13.89$81.61
Enterprise Value
$12.06B$20.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applied Digital Corporation

Applied Digital (APLD) trades at $31.50, up 8.4% today, showing strong momentum despite recent volatility. The stock maintains a neutral technical signal with mixed indicators, while fundamentals reveal aggressive growth with $144M revenue in 2025 projected to surge to $611M in 2026. The company secured $36B in contracted AI infrastructure revenue, driving investor optimism, though it operates at a net loss with negative margins. Analyst consensus is unanimously bullish with a $72.36 price target, representing 130% upside potential from current levels.

APLD presents high-growth potential as an AI infrastructure play with massive contracted backlog, but carries significant execution risk amid substantial losses and heavy capital expenditure needs. The stock's valuation appears stretched at 13.37x sales despite negative profitability, while insider selling and institutional position reductions signal caution. Investors face binary outcomes between transformative AI infrastructure success and financial strain from the company's aggressive expansion pace.

Incyte Corporation

INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.

Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applied Digital Corporation

Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.

Read more on APLD

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY